Mostrar el registro sencillo del ítem

Revisión de estudios pre-clínicos de candidatos a vacuna contra la malaria causada por Plasmodium falciparum

dc.contributor.authorCamargo Mancipe, Anny Jinethspa
dc.contributor.authorDiaz Arévalo, Dianaspa
dc.contributor.authorSalamanca, David Ricardospa
dc.contributor.authorChaparro, Laura Esperanza Cuyspa
dc.contributor.authorMancipe, Diego Fernando Camargospa
dc.date.accessioned2019-07-26 00:00:00
dc.date.accessioned2022-03-08T16:18:45Z
dc.date.available2019-07-26 00:00:00
dc.date.available2022-03-08T16:18:45Z
dc.date.issued2019-07-26
dc.identifier.issn2389-7325
dc.identifier.urihttps://repositorio.uniboyaca.edu.co/handle/uniboyaca/366
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.publisherUniversidad de Boyacáspa
dc.rightsRevista Investigación en Salud Universidad de Boyacá - 2019spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0spa
dc.sourcehttps://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/view/353spa
dc.subjectmalariaspa
dc.subjectvacunasspa
dc.subjectinmunogenicidad vacunalspa
dc.subjectPlasmodium falciparumspa
dc.subjecteficaciaspa
dc.subjectexperimentación animalspa
dc.subjectmalariaeng
dc.subjectvaccineseng
dc.subjectimmunogenicity vaccineeng
dc.subjectPlasmodium falciparumeng
dc.subjectefficacyeng
dc.subjectanimal experimentationeng
dc.subjectMaláriaeng
dc.subjectvacinaseng
dc.subjectimunogenicidade vacinaleng
dc.subjectPlasmodium falciparumeng
dc.subjecteficáciaeng
dc.subjectexperimentação animaleng
dc.titleRevisión de estudios pre-clínicos de candidatos a vacuna contra la malaria causada por Plasmodium falciparumspa
dc.typeArtículo de revistaspa
dc.typeJournal articleeng
dc.identifier.doi10.24267/23897325.353
dc.identifier.eissn2539-2018
dc.identifier.urlhttps://doi.org/10.24267/23897325.353
dc.relation.bitstreamhttps://revistasdigitales.uniboyaca.edu.co/index.php/rs/article/download/353/494
dc.relation.citationeditionNúm. 2 , Año 2019 : Revista Investigación en Salud Universidad de Boyacáspa
dc.relation.citationendpage223
dc.relation.citationissue2spa
dc.relation.citationstartpage200
dc.relation.citationvolume6spa
dc.relation.ispartofjournalRevista Investigación en Salud Universidad de Boyacáspa
dc.relation.referencesDraper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria Vaccines: Recent Advances and New Horizons. Cell Host Microbe. 2018;24:43-56. https://doi.org/10.1016/j.chom.2018.06.008 2. Miller LH, Ackerman HC, Su X, Wellems TE. Malaria biology and disease pathogenesis: insights for new treatments. Nat Med. 2013;19:156-67. https://doi.org/10.1038/nm.3073 3. Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95(6 Suppl):15-34. https://doi.org/10.4269/ajtmh.16-0141 4. Phillips MA, Burrows JN, Manyando C, van Huijsduijnen RH, Van Voorhis WC, Wells TNC. Malaria. Nat Rev Dis Primer. 2017;3:23. https://doi.org/10.1038/nrdp.2017.50 5. Cowman AF, Tonkin CJ, Tham W-H, Duraisingh MT. The Molecular Basis of Erythrocyte Invasion by Malaria Parasites. Cell Host Microbe. 2017;22(2):232-245. https://doi.org/10.1016/j.chom.2017.07.003 6. Patarroyo ME, Alba MP, Rojas-Luna R, Bermúdez A, Aza-Conde J. Functionally relevant proteins in Plasmodium falciparum host cell invasion. Immunotherapy. 2017;9:131-55. https://doi.org/10.2217/imt-2016-0091 7. Patarroyo ME, Bermúdez A, Patarroyo MA. Structural and Immunological Principles Leading to Chemically Synthesized, Multiantigenic, Multistage, Minimal Subunit-Based Vaccine Development. Chem Rev. 2011;111(5):3459-507. https://doi.org/10.1021/cr100223m 8. World Health Organization. World malaria report 2018. 2018; 1-210 p. 9. World Health Organization, World Health Organization, Global Malaria Programme. Global technical strategy for malaria, 2016-2030. World Health Organization; 2015. 1-35 p. 10. Goh YS. Mcguire D, Renia L.Vaccination With Sporozoites: Models and Correlates of Protection. Front Immunol. 2019;10:18. https://doi.org/10.3389/fimmu.2019.01227 11. De SL, Stanisic DI, van Breda K, Bellete B, Harris I, McCallum F, et al. Persistence and immunogenicity of chemically attenuated blood stage Plasmodium falciparum in Aotus monkeys. Int J Parasitol. 2016;46:581-91. https://doi.org/10.1016/j.ijpara.2016.05.002 12. Herrera S, Perlaza BL, Bonelo A, Arévalo-Herrera M. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol. 2002;32(13):1625-35. https://doi.org/10.1016/s0020-7519(02)00191-1 13. Langhorne J, Buffet P, Galinski M, Good M, Harty J, Leroy D, et al. The relevance of non-human primate and rodent malaria models for humans. Malar J. 2011;10:1-23. https://doi.org/10.1186/1475-2875-10-23 14. Nino-Vasquez JJ, Vogel D, Rodríguez R, Moreno A, Patarroyo ME, Pluschke G, et al. Sequence and diversity of DRB genes of Aotus nancymaae , a primate model for human malaria parasites. Immunogenetics. 2000;51(3):219-30. https://doi.org/10.1007/s002510050035 15. Suárez M. CF, Patarroyo MA, Patarroyo ME. Characterisation and comparative analysis of MHC-DPA1 exon 2 in the owl monkey (Aotus nancymaae). Gene.2011;470(1-2):37-45. https://doi.org/10.1016/j.gene.2010.09.006 16. Cardenas PP, Suárez CF, Martínez P, Patarroyo ME, Patarroyo MA. MHC class I genes in the owl monkey: mosaic organisation, convergence and loci diversity. Immunogenetics. 2005;56(11):818-32. https://doi.org/10.1007/s00251-004-0751-5 17. Baquero JE, Miranda S, Murillo O, Mateus H, Trujillo E, Suárez C, et al. Reference strand conformational analysis (RSCA) is a valuable tool in identifying MHC-DRB sequences in three species of Aotus monkeys. Immunogenetics. 2006;58(7):590-7. https://doi.org/10.1007/s00251-006-0101-x 18. Guerrero JE, Pacheco DP, Suárez CF, Martínez P, Aristizabal F, Moncada CA, et al. Characterizing T-cell receptor gamma-variable gene in Aotus nancymaae owl monkey peripheral blood. Tissue Antigens.2003;62(6):472-82. https://doi.org/10.1046/j.1399-0039.2003.00130.x 19. Jones TR, Obaldia N, Hoffman SL, Gramzinski RA. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg. 2000;62(6):675-80. https://doi.org/10.4269/ajtmh.2000.62.675 20. Suárez CF, Pabón L, Barrera A, Aza-Conde J, Patarroyo MA, Patarroyo ME. Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans. Biochem Biophys Res Commun. 2017;491(4):1062-9. https://doi.org/10.1016/j.bbrc.2017.08.012 21. Minkah NK, Schafer C, Kappe SHI. Humanized Mouse Models for the Study of Human Malaria Parasite Biology, Pathogenesis, and Immunity. Front Immunol. 2018;1-9. https://doi.org/10.3389/fimmu.2018.00807 22. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei. Nature. 1967;216:160-2. https://doi.org/10.1038/216160a0 23. Nussenzweig RS, Vanderberg JP, Most H, Orton C. Specificity of Protective Immunity produced by X-irradiated Plasmodium berghei Sporozoites. Nature.1969;222(5192):488-9. https://doi.org/10.1038/222488a0 24. Vanderberg JP, Nussenzweig RS, Most H, Orton CG. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. II. Effects of radiation on sporozoites. J Parasitol. 1968;54(6):1175-80. https://doi.org/10.2307/3276987 25. Nussenzweig RS, Zavala F. A Malaria Vaccine Based on a Sporozoite Antigen.NEngl J Med.1997;336(2):128-30. https://doi.org/10.1056/NEJM199701093360210 26. Nussenzweig V, Nussenzweig RS. Rationale for the Development of an Engineered Sporozoite Malaria Vaccine. Adv Immunol.1989;45:283-334. https://doi.org/10.1016/s0065-2776(08)60695-1 27. Epstein JE, Tewari K, Lyke KE, Sim BKL, Billingsley PF, Laurens MB, et al. Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity. Science. 2011;334(6055):475-80. https://doi.org/10.1126/science.1211548 28. Hill AV, Biswas S, Draper S, Rampling T, Reyes-Sandoval A. Towards a multi-antigen multi-stage malaria vaccine. Malar J. 2014;13(S1):O31. . https://doi.org/10.1186/1475-2875-13-S1-O31 29. Tolia NH, Enemark EJ, Sim BKL, Joshua-Tor L. Structural Basis for the EBA-175 Erythrocyte Invasion Pathway of the Malaria Parasite Plasmodium falciparum. Cell. 2005;122(2):183-93. https://doi.org/10.1016/j.cell.2005.05.033 30. Sim BKL, Chitnis CE, Wasniowska K, Millert LH. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. 1994;264:1941-3. https://doi.org/10.1126/science.8009226 31. Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, Liang H, et al. Protection of Aotus Monkeys by Plasmodium falciparum EBA‐175 Region II DNA Prime–Protein Boost Immunization Regimen. J Infect Dis. 2001;183(2):303-12. https://doi.org/10.1086/317933 32. Volz JC, Yap A, Sisquella X, Thompson JK, Lim NTY, Whitehead LW, et al. Essential Role of the PfRh5/PfRipr/CyRPA Complex during Plasmodium falciparum Invasion of Erythrocytes. Cell Host Microbe. 2016;20:60-71. https://doi.org/10.1016/j.chom.2016.06.004 33. Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang C-Y, et al. Naturally Acquired Antibodies Specific for Plasmodium falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection From Malaria. J Infect Dis. 2014;209:789-98. https://doi.org/10.1093/infdis/jit553 34. Patel SD, Ahouidi AD, Bei AK, Dieye TN, Mboup S, Harrison SC, et al. Plasmodium falciparum Merozoite Surface Antigen, PfRH5, Elicits Detectable Levels of Invasion-Inhibiting Antibodies in Humans. J Infect Dis. 2013;208:1679-87. https://doi.org/10.1093/infdis/jit385 35. Chen L, Xu Y, Healer J, Thompson JK, Smith BJ, Lawrence MC, et al. Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes. eLife. 2014;3:1-10. https://doi.org/10.7554/eLife.04187.001 36. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Mol Ther. 2012;20(12):2355-68. https://doi.org/10.1038/mt.2012.223 37. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med. 2008;14:819-21. https://doi.org/10.1038/nm.1850 38. de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P, et al. The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. J Immunol. 2011;187:2602-16. https://doi.org/10.4049/jimmunol.1101004 39. Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ, et al. A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host Microbe. 2015;17:130-9. https://doi.org/10.1016/j.chom.2014.11.017 40. Srinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc Natl Acad Sci. 2011;108:13275-80. https://doi.org/10.1073/pnas.1110303108 41. Tyler JS, Boothroyd JC. The C-Terminus of Toxoplasma RON2 Provides the Crucial Link between AMA1 and the Host-Associated Invasion Complex. Soldati-Favre D, editor. PLoS Pathog. 2011;7:1-12. https://doi.org/10.1371/journal.ppat.1001282 42. Mital J, Meissner M, Soldati D, Ward GE. Conditional Expression of Toxoplasma gondii Apical Membrane Antigen-1 (TgAMA1) Demonstrates That TgAMA1 Plays a Critical Role in Host Cell Invasion. Mol Biol Cell. 2005;16(9):4341-9. https://doi.org/10.1091/mbc.e05-04-0281 43. Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, et al. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. J Infect Dis. 2016;213:1743-51. https://doi.org/10.1093/infdis/jiw039 44. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A. Beeson JG, editor. PLoS ONE. 2009;4(4):1-13. https://doi.org/10.1371/journal.pone.0005254 45. Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, et al. A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. Npj Vaccines. 2017;2(1):1-10. https://doi.org/10.1038/s41541-017-0015-7 46. Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Malar J. 2016;1-7. https://doi.org/10.1186/s12936-016-1226-5 47. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. N Engl J Med. 2008;359:2521-32. https://doi.org/10.1056/NEJMoa0807381 48. Brian Greenwood. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet. 2015;386:60721-8. https://doi.org/10.1016/S0140-6736(15)60721-8 49. Vekemans J, Leach A, Cohen J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine. 2009;27:67-71. https://doi.org/10.1016/j.vaccine.2009.10.013 50. Cohen J, Nussenzweig V, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum Vaccin. 2010;6:90-6. https://doi.org/10.4161/hv.6.1.9677 51. Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, et al. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine. 2009;28(2):452-62. https://doi.org/10.1016/j.vaccine.2009.10.022 52. Kester KE, Stewart AV, Walsh DS, Voss G, Tongtawe P, Ballou WR, et al. Safety and immunogenicity of RTS,S + TRAP malaria vaccine, formulated in the AS02A adjuvant system, in infant Rhesus monkeys. Am J Trop Med Hyg. 2004;70:499-509. https://doi.org/10.4269/ajtmh.2004.70.499 53. Kester KE, Cummings JF, Ofori‐Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection. J Infect Dis. 2009;200:337-46. https://doi.org/10.1086/600120 54. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6:723-39. https://doi.org/10.1586/14760584.6.5.723 55. Walsh D, Gettayacamin M, Leitner W, Lyon J, Stewart V, Marit G, et al. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A. Vaccine. 2006;24:4167-78. https://doi.org/10.1016/j.vaccine.2006.02.041 56. Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, et al. Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone. Infect Immun. 2007;75(5):2283-90. https://doi.org/10.1128/IAI.01879-06 57. Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine. 2006;(15):2850-9. https://doi: 10.1016/j.vaccine.2005.12.041 58. GwADz RW, Cochrane H, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ. 1979;165-73. 59. Hoffman SL, Goh LML, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of Humans against Malaria by Immunization with Radiation‐Attenuated Plasmodium falciparum Sporozoites. J Infect Dis. 2002;185:1155-64. https://doi.org/10.1086/339409 60. Patarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, Martínez A et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature. 1987;328:629-32. https://doi.org/10.1038/328629a0 61. Noya G. O, Berti YG, Noya BA d., Borges R, Zerpa N, Urb ez JD, et al. A Population-Based Clinical Trial with the SPf66 Synthetic Plasmodium falciparum Malaria Vaccine in Venezuela. J Infect Dis. 1994;170:396-402. https://doi.org/10.1093/infdis/170.2.396 62. Sempertegui F, Estrella B, Moscoso J, Piedrahita L, Hernández D, Gaybor J et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodiumfalciparum infection in a randomized double-blind placebo-controlled field trial fin an endemic area of Ecuador. Vaccine. 1994;337-42. https://doi.org/10.1016/0264-410X(94)90098-1 63. Valero M, Amador R, Aponte J, Narvaez A, Galindo C, Silva Y et al. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine. 1996;14:1466-70. https://doi.org/10.1016/S0264-410X(96)00070-9 64. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. The Lancet. 1993;341:705-10. https://doi.org/10.1016/0140-6736(93)90483-W 65. Patarroyo ME, Patarroyo MA. Emerging Rules for Subunit-Based, Multiantigenic, Multistage Chemically Synthesized Vaccines. Acc Chem Res. 2008;41:377-86. https://doi.org/10.1021/ar700120t 66. Vaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest. 2012;122:3618-28. https://doi.org/10.1172/JCI62684 67. Mikolajczak SA, Vaughan AM, Kangwanrangsan N, Roobsoong W, Fishbaugher M, Yimamnuaychok N, et al. Plasmodium vivax Liver Stage Development and Hypnozoite Persistence in Human Liver-Chimeric Mice. Cell Host Microbe. 2015;17(4):526-35. https://doi.org/10.1016/j.chom.2015.02.011 68. Sack BK, Mikolajczak SA, Fishbaugher M, Vaughan AM, Flannery EL, Nguyen T, et al. Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice. Npj Vaccines. 2017;2(1):1-11. https://doi.org/10.1038/s41541-017-0028-2 69. Weiss GE, Crabb BS, Gilson PR. Overlaying Molecular and Temporal Aspects of Malaria Parasite Invasion. Trends Parasitol. 2016;32(4):284-95. https://doi.org/10.1016/j.pt.2015.12.007 70. Weiss GE, Gilson PR, Taechalertpaisarn T, Tham W-H, de Jong NWM, Harvey KL, et al. Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes. Blackman MJ, editor. PLOS Pathog. 2015;11(2):e1004670. https://doi.org/10.1371/journal.ppat.1004670 71. Moser KA, Drábek EF, Dwivedi A, Crabtree J, Stucke EM, Dara A, et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genomics; 2019 https://doi.org/10.1101/684175 72. Lyke KE, Fernández-Viňa MA, Cao K, Hollenbach J, Coulibaly D, Kone AK, et al. Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens. 2011;77(6):562-71. https://doi.org/10.1111/j.1399-0039.2011.01661.x 73. Matern BM, Olieslagers TI, Voorter CEM, Groeneweg M, Tilanus MGJ. Insights into the polymorphism in HLA‐DRA and its evolutionary relationship with HLA Haplotypes. HLA. 2019;95(2):13730. https://doi.org/10.1111/tan.13730 74. La Gruta NL, Gras S, Daley SR, Thomas PG, Rossjohn J. Understanding the drivers of MHC restriction of T cell receptors. Nat Rev Immunol.2018;18(7):467-78. https://doi.org/10.1038/ s41577-018-0007-5spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.spa
dc.title.translatedReview of preclinical studies of candidates for malaria vaccine caused by Plasmodium falciparumeng
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREVspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa


Ficheros en el ítem

FicherosTamañoFormatoVer
Revista Investig. Salud Univ. Boyacá-353.pdf546.3Kbapplication/pdfVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Revista Investigación en Salud Universidad de Boyacá - 2019
Excepto si se señala otra cosa, la licencia del ítem se describe como Revista Investigación en Salud Universidad de Boyacá - 2019